Skip to main content

Table 2 Time to resolution of clinical symptoms

From: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

 

Camostat mesilate (N = 53)

Placebo (N = 52)

Events, n (%)

23 (43.4)

23 (44.2)

Median (95% CI) (days)

13.0 (10.0–n/c)

12.0 (10.0–n/c)

25th to 75th percentile

7.0–15.0

9.0–n/c

Range

2–16 + 

2–14 + 

  1.  + censored, CI confidence interval, n/c not calculable
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us